Navigation Links
Antipsychotic Iloperidone Results Show Favorable Akathisia Profile

emor, slurred speech, restlessness and involuntary muscle movement) during the course of the study. In contrast, 5% of low-dose and 11% of high-dose iloperidone patients received anticholinergic medication.

"Iloperidone may be less likely to worsen akathisia because of its novel mechanism of action," said Paolo Baroldi, M.D., Ph.D., Chief Medical Officer, Vanda Pharmaceuticals Inc. "Akathisia is believed to be due to D2 activation, which is not present with iloperidone."

About the Study

In this Phase III randomized, double-blind, placebo- and risperidone- controlled, international multi-center six-week study conducted by Novartis, patients were randomized to one of four treatment groups: iloperidone low- dose (12.16 mg/d, n=244), iloperidone high-dose (20.24 mg/d, n=145), risperidone (6.8 mg/d, n=157) or placebo (n=160).

Patients enrolled in the study were 62% male (n=435) and 38% female (n=271), approximately 39 years of age, and had a diagnosis of schizophrenia or schizoaffective disorder with a Positive and Negative Syndrome Scale (PANSS) score greater than or equal to 60 at baseline.

Anticholinergic drugs for the treatment of EPS were permitted during the two-day placebo run-in period. EPS must have improved and anticholinergics discontinued for more than 24 hours prior to baseline measurement.

Changes in akathisia were measured weekly by the BAS and the Extrapyramidal Symptom Rating Scale (ESRS) from baseline to the six-week end point for patients in all treatment groups. Categorical analysis was conducted to determine the percentage of patients with akathisia that worsened, remained unchanged, or improved, from baseline, during the treatment period. Use of anticholinergics (benztropine or biperiden) was allowed during the double-blind phase in all four groups for treatment-emergent EPS, after assessment was completed by the EPS rating scales.

About Iloperidone

Iloperidone is an atypical antipsychotic, wit
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia
2. Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007 American Psychiatric Association Annual Meeting
3. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
4. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:7/2/2015)... MUMBAI , July 2, 2015 ... equity stake in ZAO "Biocom" in Russia ... foray into the Russian pharmaceutical market which recorded RUB 765 ... 10 pharmaceutical markets in the world in 2014 (IMS Health). ... growth and expected to continue with this trend, projecting ...
(Date:7/2/2015)... 2, 2015 The report "Silage ... Species (Lactobacillus, Pediococcus & Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), ... 2020", Silage Inoculants & Enzymes Market is expected to ... 4.0% from 2015 to 2020. Browse ... through 194 P ages and an ...
(Date:7/2/2015)... 2015 BGI gab heute bekannt, ... vom American College of Pathologists (CAP) akkreditiert ... erste klinische Next-Generation-Sequencing Labor, das in ... und somit die höchsten Standards an klinischer ... FDA - 21 CFR Part 11 konformen ...
Breaking Medicine Technology:Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
... BROWNE, MORGAN FREEMAN, SAMUEL L. JACKSON, GEORGE LOPEZ, ... Oct. 24 On Thursday, November 15, 2007,Artists for a ... benefit, at The Wiltern in Los Angeles. The evening combines,the ... -- from the personal,to the global -- and make a ...
... Support Preclinical Development of Intradigm,s ICS-283, ... Corporation, a,leading developer of targeted, systemic RNA ... demonstrated the company,s,TargeTran(TM) delivery system is capable ... small interfering RNAs (siRNAs) that suppress,tumor-induced angiogenesis ...
Cached Medicine Technology:Artists for a New South Africa Will be 'Shaking The Blues' at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb' Mo', Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles 2Artists for a New South Africa Will be 'Shaking The Blues' at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb' Mo', Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles 3Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 2Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 3
(Date:7/2/2015)... ... July 02, 2015 , ... ... Krishnareddy, M.D., to the orthopedic and spine surgery team at their Anaheim clinic. ... bursitis, and tendonitis. Along with the spine and spine surgery, Dr. Krishnareddy also ...
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ... procedures and executing them with care and precision. There is an art and ... has had the honor of successfully reshaping the facial features and lives of ...
(Date:7/2/2015)... ... July 02, 2015 , ... Breakthrough technologies are now available ... Lev Kalika, founder of New York Dynamic Neuromuscular Rehabilitation & Physical Therapy ... treatment of back, hip, knee and shoulder pain as well as sports injury ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... Research (CVR) recently received nearly $4 million through five federal grants to ... vaccines and therapies against the deadly diseases. , The research will be ...
(Date:7/2/2015)... ... July 02, 2015 , ... eHuman Digital ... new release of their flagship product, 3D Tooth Atlas, version 7.6. This release ... and new tutorial videos. This latest release of the 3D Tooth Atlas offers ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 2Health News:Healthpointe Welcomes Dr. Divakar R. Krishnareddy to its Orthopedic Team in Anaheim 3Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:eHuman Digital Anatomy Releases 3D Tooth Atlas version 7.6 2
... to lead BCBSIL,s sales and,marketing, CHICAGO, May ... senior vice president, Local and Consumer Markets, for,Blue ... his new role, Freer,will oversee small, mid-market, and ... as well as manage HMO Illinois. Freer also,will ...
... teach low-income adults about healthy food choices is a ... benefits achieved, reports a cost-effectiveness study in the May/June ... http://www.jneb.org/ ). , Led by Jamie Dollahite, Ph.D., R.D., ... evaluations to assess the costs versus benefits of the ...
... 13 Medivation, Inc.,(Nasdaq: MDVN ) today announced that David ... conferences., -- Rodman & Renshaw 5th Annual Global Healthcare ... p.m. local time at Le Meridien Beach Plaza Hotel in ... Generic Pharmaceuticals Conference on Wednesday, May 28 ...
... May 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... of pharmaceutical, medicinal and diagnostic products in China,today ... at 5:00 p.m. Eastern,Time on May 15, 2008 ... Joining Mr. Yan-qing Liu, Chairman, CEO and ...
... The Quantum Group,(Amex: QGP ) today announced ... has expanded its relationship with one of its ... of its Community Health,System. This expanded relationship will ... Medicaid patients. The contract will initially cover,South Florida, ...
... Fla., May 13 A complete review of ... a multi-disciplinary and,collaborative approach to weight loss, according ... The use of several proven,weight management strategies in ... the greatest likelihood of success., NBC,s hit ...
Cached Medicine News:Health News:Blue Cross and Blue Shield of Illinois Names New Vice President, Local and Consumer Markets 2Health News:Expanded food and nutrition program shows $10 benefit for each $1 spent 2Health News:Medivation Announces Participation in Upcoming Conferences 2Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:The Quantum Group Executes First Medicaid Service Contract with HMO 2Health News:The Quantum Group Executes First Medicaid Service Contract with HMO 3Health News:Research Converging in Favor of New Approach to U.S. Weight Problem 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: